^
Association details:
| Biomarker: | KIT overexpression |
|---|---|
| Cancer: | Melanoma |
| Drug: | dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) |
| Direction: | Resistant |
Evidence:
Source:
Title:
A phase II trial of dasatinib in advanced melanoma
Excerpt:
Therefore, in patients demonstrating a tumor response of any kind to dasatinib, and in selected other patients in whom c-kit overexpression and/or mutation was expected based on prior literature reports, we determined c-kit mutation and/or expression by immunohistochemistry (IHC) in pre-treatment tumor samples.
DOI:
10.1002/cncr.25766
